Sustained Clinical Benefit After 3 Year Follow Up in Scleroderma Trial
SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) Topline review of early three-year follow-up data from the SCLERADEC I trial shows sustained benefit in treated patients over baseline in major study endpoints. The data …